Skip to main content

Advertisement

Table 4 Mean survival based on CTC positivity, TIMP-1 and CAIX levels

From: Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer

  PFS in months Pvalue OS in months Pvalue
CTC negative   < 0.011   < 0.011
TIMP-1     
   Non elevated 12.3(10.6-14.1) < 0.012 21.4 (20.3-22.6) < 0.01
   Elevated 4.4 (2.8-6.0)   12.0 (8.2-15.7)  
CTC positive     
TIMP-1     
   Non elevated 9.5 (7.6-11.4) 0.81 15.5 (13.3-17.7) 0.151
   Elevated 8.5 (6.2-10.8)   12.0 (9.4-14.6)  
CTC negative   < 0.011   < 0.011
CAIX     
   Non elevated 11.6 (9.8-13.5) 0.06 21.3 (20.0-22.6) < 0.01
   Elevated 8.1 (5.6-10.6)   15.9 (12.8-19.0)  
CTC positive     
CAIX     
   Non elevated 11.0(8.7-13.1) < 0.05 16.2 (14.0-18.4) < 0.05
   Elevated 7.1(5.2-9.0)   11.8 (9.5-14.1)  
  1. 1P value for comparing differences between all four groups, 2comparing survival differences for comparing marker positivity within CTC negative and positive patients
  2. CAIX, carbonic anhydrase IX; CTC, circulating tumor cell; OS, overall survival; PFS, progression-free survival; TIMP, tissue inhibitor of metalloproteinase.